For the roughly one in five American adults living with an anxiety disorder or persistent low mood, the front door to care has not changed much in a decade: a primary care visit, a PHQ-9 screener, and often a prescription for an SSRI that takes four to six weeks to titrate. PYM, the Los Angeles supplement company founded by Zak Williams and Olivia June in 2018, is making a different pitch to that same patient population. Its flagship product, a chewable made with amino acids, vitamins and minerals, is sold direct to consumers who want something to reach for between the therapist appointment and the prescription pad [LinkedIn].
The disease state PYM is speaking to is not formally diagnosed major depressive disorder or generalized anxiety disorder, and the company is careful about that line. Its supplements are regulated by the FDA as dietary supplements under DSHEA, not as drugs, which means PYM cannot claim to treat or cure a psychiatric condition. What it can do, and what it does, is market ingredients like L-theanine and rhodiola to adults describing everyday stress, low mood, and what Williams has called the need for "mental hygiene" [Fortune, 2023]. The company frames the chews as a daily practice rather than a clinical intervention, which matters both for regulatory posture and for who the target customer turns out to be.
The bet
PYM sells through its own e-commerce site, youcanpym.com, with mood chews as the lead SKU and a small adjacent line of stress and sleep products [PYM]. The wedge is straightforward: meet a consumer who is already buying magnesium, ashwagandha, or melatonin on Amazon, and offer a brand built specifically around mood and neurotransmitter support, with founder credibility that other supplement brands cannot replicate. Williams has been public about founding the company after the death of his father, the actor Robin Williams, in 2014, and about his own experience with depression [Fortune, 2023]. That story is the marketing, but it is also the strategic moat in a category where consumer trust is the scarce resource.
The standard of care for the patients PYM is adjacent to looks like this today: for clinically diagnosed depression or anxiety, first-line treatment is typically an SSRI or SNRI, often combined with cognitive behavioral therapy, with response rates in the 40 to 60 percent range and a multi-week onset. For subclinical symptoms, which is most of the addressable market, primary care physicians often suggest exercise, sleep hygiene, and over-the-counter supplements without strong guidance on which ones. PYM is positioning itself in that gap, not against the prescription, but alongside it.
Why it could be big
The tailwinds are real. Mental health spending in the United States has climbed sharply since 2020, and the supplement category for mood and stress has been one of the fastest growing segments in consumer wellness. Adapt VC, which backed PYM's seed round, has built a portfolio around brands selling to consumers who treat wellness as identity rather than as occasional purchase [Adapt VC]. The company raised approximately $1 million in its seed round, a modest figure that fits a DTC supplement company building toward repeat purchase economics rather than burning capital on customer acquisition [Inc].
Seed funding raised | 1 | $M
If PYM can convert the founder story into durable subscription revenue, the upside is a brand that occupies the mental wellness shelf the way Olly occupies the multivitamin shelf or Liquid Death occupies water. The category is large, fragmented, and structurally underbranded. A company that becomes the default name in mood support, even at single-digit market share, becomes an acquisition target for the strategics who already own most of the supplement aisle.
The team
Zak Williams holds a BA in linguistics and literature from NYU and an MBA from Columbia Business School, and his earlier career included a stint as an assistant producer at Electronic Arts before he moved into film production and angel investing in healthcare and technology [Crunchbase] [The Org] [Milken Institute]. He is the public face of the company and its CEO. Co-founder Olivia June, his wife, is also founder and CEO of VINA and previously led community development at RocketSpace; she attended Chapman University and has spoken publicly about her own use of amino acid therapy informing the product formulation [Crunchbase] [PYM Website]. The team also extended the brand beyond pure supplements: Williams has separately partnered with a San Francisco startup to explore AI as a mental health resource, suggesting the company is thinking past the chew as the only product [San Francisco Chronicle].
The honest counterfactual
The most credible concern is the evidence base. Amino acid and botanical supplements for mood have a real but uneven literature: L-theanine has small randomized trials supporting modest anxiolytic effects, and rhodiola has been studied for fatigue, but no PYM formulation has been through a peer-reviewed clinical trial of its own, and the company does not claim one. Bears will say that without trial data, PYM competes on brand and founder narrative against thousands of other supplement SKUs, and that the FDA's structure-function claim regime gives it limited room to make the kind of efficacy statements that would let it pull share from prescription alternatives. Bulls will answer that the supplement category has never been won on RCTs; it is won on trust, repeat purchase, and shelf presence, and that PYM has a more coherent founder story and a more focused indication than almost any competitor in the mood category. Both readings are defensible, and the next two years of repeat-purchase data will decide which one is right.
What to watch
The milestones to watch over the next twelve months are retail expansion beyond the company's own site, any move into a Series A round (the seed was small enough that a priced round would be a meaningful signal), and whether PYM begins to publish or sponsor clinical work on its formulations. A single well-designed trial, even a small one, would change how the brand can talk about itself and would give it defensible ground against the category's long tail. For a company built on the premise that mental hygiene deserves the same daily ritual as brushing teeth, the next product launch and the next piece of evidence are the same story.
Pulse Raman covers biotech, digital health, and clinical AI for Startuply.